EE426 A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.727
https://www.valueinhealthjournal.com/article/S1098-3015(23)00827-6/fulltext
Section Title :
Section Order :
10200
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00827-6&doi=10.1016/j.jval.2023.03.727